prostate cancer (nmCRPC)
Oncology · 2018–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| enzalutamide Non-metastatic castration-resistant prostate cancer (m0CRPC) in patients with PSA doubling time of 10 months or less, WHO performance score of 0 or 1, and no… | Mar 2022 | Recommended with restriction | unclear |
| darolutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined as those with… | Mar 2021 | Not recommended | input received Prostate Cancer Foundation · Medical Oncology Group |
| apalutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases (defined by prostate specific… | Nov 2021 | Recommended with restriction | input received Prostate Cancer Foundation · Medical Oncology Group |
| darolutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined as prostate-specific… | Jul 2020 | Not recommended | 3 individuals Geelong Prostate Support Group · Prostate Cancer Foundation · Medical Oncology Group |
| apalutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined by prostate-specific… | Nov 2020 | Not recommended | 2 individuals Prostate Cancer Foundation · Medical Oncology Group |
| apalutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined as PSA doubling time ≤10… | Jul 2019 | Not recommended | 6 individuals Geelong Prostate Support Group · Medical Oncology Group |
| apalutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined as PSA doubling time ≤10… | Nov 2018 | Not recommended | 9 individuals Medical Oncology Group |
Who spoke
Medical Oncology Group · Prostate Cancer Foundation · Geelong Prostate Support Group
What the PBS pays
$378M in government benefit over 2024–25, across 108,004 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| enzalutamide | $179.9M |
| darolutamide | $147.6M |
| apalutamide | $50.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 2 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| enzalutamideEnzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) | TA994 | terminated | 2024-08 |
| apalutamideApalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | recommended restricted | 2021-10 |
| darolutamideDarolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | recommended restricted | 2020-11 |
| enzalutamideEnzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | not recommended | 2019-05 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.